Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIM-DePisT
2024-518259-49-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in Schizophrenia Spectrum Disorders (SSD) and mental disorder (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Remission of psychiatric symptoms at 3 months. Planned start Oct 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
Schizophrenia Spectrum Disorders (SSD)mental disorder
Beyond the preview
Go deeper on 2024-518259-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518259-49-00.